A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of alpha(2) integrin inhibitor E7820 in patients with advanced solid tumors

B M Kerklaan, S Slater, M Flynn, A Greystoke, PO Witteveen, M Megui-Roelvink, F Vos, E Dean, L Reyderman, L Ottesen, M Ranson, Martijn Lolkema, R Plummer, R Kristeleit, TRJ Evans, JHM Schellens

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)329-337
Number of pages9
JournalInvestigational New Drugs
Issue number3
Publication statusPublished - 2016

Research programs

  • EMC MM-03-86-08

Cite this